Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

3
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (1)

Searched Name

F. Bewicke-Copley

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number

Citation Analysis

Korfi K, Araf S, Bewicke-Copley F, Kumar E, Cummin T, Ashton-Key M, Barrans S, Van Hoppe S, Burton C, Elshiekh M, Rule S, Crosbie N, Clear A, Calaminici M, Menon G, Sha C, Bentley M, Nagano A, Davies A, Painter D, Smith A, Okosun J, Gribben J, Naresh K, Westhead D, Wang J, Johnson P, Fitzgibbon J. LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.100_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]

Affiliation(s)

K. Korfi Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
S. Araf Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
F. Bewicke-Copley Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
E. Kumar Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
T. Cummin Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
M. Ashton-Key Cellular Pathology; University Hospital Southampton NHS Foundation Trust; Southampton United Kingdom
S. Barrans HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
S. Van Hoppe HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
C. Burton HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
M. Elshiekh Cellular & Molecular Pathology; Imperial College NHS Trust & Imperial College London; London United Kingdom
S. Rule Department of Haematology; Derriford Hospital, University of Plymouth; Plymouth United Kingdom
N. Crosbie Department of Haematology; University Hospitals Plymouth NHS Trust; Plymouth United Kingdom
A. Clear Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
M. Calaminici Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
G. Menon Haemato-Oncology Diagnostic Service; Liverpool Clinical Laboratories; Liverpool United Kingdom
C. Sha School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
M. Bentley School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
A. Nagano Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
A. Davies Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
D. Painter Epidemiology and Cancer Statistics Group; University of York; York United Kingdom
A. Smith Epidemiology and Cancer Statistics Group; University of York; York United Kingdom
J. Okosun Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
J. Gribben Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
K.N. Naresh Cellular & Molecular Pathology; Imperial College NHS Trust & Imperial College London; London United Kingdom
D. Westhead School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
J. Wang Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
P. Johnson Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
J. Fitzgibbon Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom

Collapse

Kumar E, Korfi K, Bewicke-Copley F, Witzig T, Leukam M, Ansell S, Scott J, Rallis K, Clear A, Efeyan A, Calaminici M, Wang J, Okosun J, Smith S, Novak A, Fitzgibbon J. MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hemasphere 2019. [DOI: 10.1097/02014419-201906001-00412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open

Kumar E, Korfi K, Bewicke-Copley F, Witzig T, Leukam M, Ansell S, Scott J, Rallis K, Clear A, Efeyan A, Calaminici M, Wang J, Okosun J, Smith S, Novak A, Fitzgibbon J. PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000560152.86937.ed] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open